How Effective Is Oxycodone for Nerve Pain?

Oxycodone provides modest relief for certain types of nerve pain, but the overall evidence supporting its use is surprisingly thin and rated very low quality by major reviewers. In the largest systematic review available, roughly 44% of people with painful diabetic neuropathy got meaningful relief from oxycodone compared with 27% on placebo, but side effects were common and the studies were small and short. Clinical guidelines consistently place oxycodone and other strong opioids as a third-line option, meaning doctors are expected to try several other drug classes first.

What the Best Available Evidence Actually Shows

The most comprehensive look at this question comes from a Cochrane systematic review that pooled data from five studies involving 687 participants. Most had painful diabetic neuropathy, with a smaller group suffering from postherpetic neuralgia (the lingering nerve pain that follows shingles). None of the included studies reported on the gold-standard outcome of at least 50% pain relief. Three studies with 537 participants did report a slightly lower bar, at least 30% pain relief, and found that 44% of people taking oxycodone reached that threshold compared with 27% on placebo. The number needed to treat for one additional person to benefit was about 6, which in pain medicine is a middling result at best.¹

The flip side of that benefit is a steep rate of side effects. About 86% of people on oxycodone experienced adverse events versus 63% on placebo, giving a number needed to harm of roughly 4. In practical terms, you are more likely to experience a side effect from oxycodone than to get meaningful pain relief from it. The typical complaints were the ones you would expect from an opioid: constipation, drowsiness, nausea, and dizziness. Serious adverse events and dropouts due to side effects were not statistically different between the oxycodone and placebo groups, which at least suggests that most side effects were tolerable enough for people to stay in the trials.¹

The Cochrane reviewers downgraded their confidence in all of these findings to very low quality, citing problems with the study methods, differences in the types of pain being studied, and the small number of participants overall. Their blunt conclusion in the earlier version of the review was that there is “no convincing, unbiased evidence” that oxycodone is of value in treating painful diabetic neuropathy or postherpetic neuralgia.²

Diabetic Neuropathy Trials in Detail

Most of the clinical evidence for oxycodone and nerve pain comes from studies in painful diabetic neuropathy, a condition where damaged nerves in the feet and legs produce burning, tingling, or shooting pain. Two randomized controlled trials stand out. In one, controlled-release oxycodone at an average dose of about 37 mg per day lowered average daily pain scores from about 5.3 on a 0-to-10 scale with placebo down to 4.1 with oxycodone over a six-week treatment period.³

A second trial in the same population reported a more dramatic result. Mean daily pain dropped from about 49 mm on a 100-mm visual scale with placebo to about 22 mm with oxycodone, and the number needed to treat for one person to achieve at least 50% pain relief was 2.6, a much stronger result than the pooled Cochrane figure. That study also found improvements in total pain and disability scores.⁴

The discrepancy between that study’s strong numbers and the tepid pooled results is worth noting. Small trials can produce impressive-looking results by chance. When the data from multiple small studies get combined, the effect shrinks, which is exactly what happened here. This is why the Cochrane team and clinical guideline panels urge caution: any single trial can look better (or worse) than the real underlying effect.

Postherpetic Neuralgia

Postherpetic neuralgia, the burning or stabbing pain that persists after a shingles rash heals, has been studied separately. One randomized crossover trial enrolled 50 patients with an average age around 70 and an average daily oxycodone dose of about 45 mg. Compared with placebo, oxycodone reduced steady pain, touch-evoked pain (allodynia), and spontaneous shooting pain, all by a statistically meaningful margin.⁵

A postmarketing surveillance study of controlled-release oxycodone tablets for postherpetic neuralgia found that nearly all patients (about 98%) reported some response by the end of eight weeks of treatment, and that pain dropped quickly in the first week.⁶ That study was not blinded or placebo-controlled, however, so those numbers should be taken with a large grain of salt. Open-label surveillance studies tend to overstate benefit because both doctors and patients expect the drug to work.

A more interesting finding came from a trial testing a transdermal oxycodone patch applied directly to the painful area. The patch did not significantly improve average pain scores compared with a vehicle patch for the overall group of postherpetic neuralgia patients, although a small subgroup with high levels of tingling sensations showed a trend toward improvement. Systemic absorption was low and the patch was well tolerated, but it did not work for the condition as a whole.⁷

Nerve Pain from Spinal Cord Injury

Neuropathic pain after spinal cord injury is notoriously difficult to treat. One open-label study followed 54 spinal cord-injured patients, most of whom were already taking an anticonvulsant medication. Adding oxycodone dropped their average pain scores from about 7.1 down to 4.3 on a 10-point scale over three months, and their quality-of-life index more than doubled. No patient reported worse pain during the study.⁸

The quality-of-life improvement is noteworthy because nerve pain from spinal cord injury does not just cause discomfort; it frequently disrupts sleep, limits physical activity, and erodes mood. In this study, no patient got worse on measures of pain-related physical activity or sleep disruption, and the overall quality-of-life preference index climbed significantly.⁹ This was not a placebo-controlled trial, though, so placebo effects, natural improvement over time, and observer bias could all inflate the apparent benefit.

Where Guidelines Place Oxycodone

Every major treatment guideline for neuropathic pain positions strong opioids like oxycodone as a second- or third-line treatment. The medications recommended first are antidepressants (particularly tricyclics like amitriptyline and serotonin-norepinephrine reuptake inhibitors like duloxetine) and anticonvulsants (gabapentin and pregabalin).¹⁰ An international consensus panel gave strong opioids only a weak recommendation, proposing them as third-line treatment alongside botulinum toxin injections for peripheral nerve pain.¹¹

The Canadian Pain Society similarly recommended tramadol and controlled-release opioid analgesics as third-line agents for moderate to severe neuropathic pain.¹² A separate set of recommendations was slightly more permissive, suggesting opioids as second-line treatments that could move to first-line “in certain clinical circumstances,” such as during acute flare-ups or when first-line drugs are contraindicated.¹³

A systematic review of painful peripheral neuropathy treatments gave oxycodone its best marks not as a standalone drug but as an add-on therapy, rating it at level II evidence for painful diabetic polyneuropathy in that role. The first-line drugs all had level II evidence as monotherapies.¹⁴

Adding Oxycodone to Gabapentin or Pregabalin

Because opioids and anticonvulsants work through different mechanisms, combining them has been tested to see if the pairing provides more relief than either drug alone. The results are mixed but lean positive for one combination and negative for another.

In a trial of patients with painful diabetic neuropathy who were already on gabapentin but still had inadequate pain control, adding controlled-release oxycodone reduced pain scores by about 33% from baseline. The combination significantly outperformed gabapentin plus placebo on pain relief, need for rescue medication, and nights of disturbed sleep. Only 14% of patients in the combination group dropped out for lack of effect, compared with 54% in the gabapentin-plus-placebo group.¹⁵

The story with pregabalin is less encouraging. A randomized trial tested adding a low dose of oxycodone (10 mg per day) to pregabalin in patients with postherpetic neuralgia or painful diabetic neuropathy. The combination was no better than pregabalin plus placebo. The authors concluded that this low dose of oxycodone did not enhance pregabalin’s pain-relieving effect.¹⁶

An Italian multicenter study, however, found that both oxycodone monotherapy and the combination of oxycodone plus pregabalin outperformed pregabalin alone, with pain reductions of about 76% and 80% respectively versus 46% for pregabalin monotherapy. The combination also had a better safety profile than pregabalin alone.¹⁷ The conflicting results between these trials could reflect differences in oxycodone dosing, patient populations, or study design. What seems consistent is that when oxycodone is added at a sufficient dose to an anticonvulsant, the combination can help people who were not adequately controlled on the anticonvulsant alone.

Why Oxycodone May Act Differently from Other Opioids on Nerve Pain

One reason oxycodone gets studied for nerve pain specifically, rather than opioids as a class, is that it appears to work through a different set of receptors than morphine. In animal models of neuropathic pain, oxycodone maintained its pain-relieving effect for months in diabetic rats while morphine lost effectiveness entirely. The research pointed to oxycodone binding with relatively high affinity to a subtype of kappa opioid receptor, distinct from the mu-opioid receptor that morphine primarily targets.¹⁸

Separate research on chemotherapy-induced neuropathic pain in animals found that chronic oxycodone treatment increased the expression of a type of GABA receptor on sensory nerve fibers, which may counteract the heightened nerve excitability that causes neuropathic pain. When researchers blocked those GABA receptors, oxycodone’s pain-relieving effect disappeared, supporting the idea that oxycodone engages the spinal GABA system in a way that other opioids may not.¹⁹

This is still mostly preclinical work. The receptor-level differences between oxycodone and morphine are well documented in animal studies, but translating animal pain models to human experience is famously unreliable. There is also evidence that neuropathic pain itself changes opioid receptors in the brainstem: certain receptor types get downregulated, which could explain why opioids in general tend to be less effective for nerve pain than for other kinds of pain.²⁰

Tolerance, Dependence, and Long-Term Considerations

The elephant in the room with any opioid for chronic pain is tolerance (needing higher doses over time to get the same relief) and the risk of dependence or addiction. Animal research suggests that oxycodone’s tolerance profile may differ somewhat from morphine’s. In one study, chronic oxycodone did not produce the same kind of pronociceptive changes in brainstem pain-control neurons that chronic morphine did, suggesting that at least one pathway toward opioid-induced increased pain sensitivity may be less of an issue with oxycodone.²¹ That said, tolerance to oxycodone absolutely does develop. In rats, twice-daily dosing for one week led to significant loss of pain-relieving effect.²²

On the human side, a three-year registry study of people taking controlled-release oxycodone for non-cancer pain found that investigators identified possible drug misuse in about 2.6% of cases, with no evidence of new-onset addiction.²³ Registry studies like this one depend on investigators noticing and reporting misuse, so the true rate could be higher. Still, under structured medical supervision with careful patient selection, the risk of outright addiction appears lower than the general public often fears, though it is never zero. Physical dependence, meaning that stopping the drug abruptly causes withdrawal symptoms, is a separate phenomenon that develops predictably in almost anyone taking opioids regularly for more than a few weeks.

Genetic Variation in Oxycodone Response

Not everyone metabolizes oxycodone the same way, and this affects how much pain relief you get. Oxycodone is broken down in the liver partly by the enzyme CYP2D6, which converts it into oxymorphone, a potent active metabolite. People who carry gene variants that make this enzyme sluggish (known as poor metabolizers) get less pain relief from oxycodone. In one experimental study, poor metabolizers had lower oxymorphone levels in their blood and experienced less pain-threshold improvement compared with people whose CYP2D6 enzyme worked normally. The difference in pain-relief measures ranged from about 10 to 12 percentage points across several types of experimental pain.²⁴

The frequency of poor CYP2D6 metabolism varies across ethnic groups. Roughly 5 to 10% of people of European descent are poor metabolizers, while the rates differ in other populations. If you have tried oxycodone and found that it did not help your nerve pain even at typical doses, genetic variation in this enzyme is one possible explanation. Some pain clinics now offer pharmacogenomic testing that can identify poor metabolizers before they spend weeks titrating a drug that their body cannot fully activate.

Controlled-Release Versus Immediate-Release Formulations

Oxycodone for chronic pain is usually prescribed in a controlled-release formulation, which releases the drug slowly over 12 hours. A randomized comparison in chronic pain patients found that controlled-release and immediate-release oxycodone maintained essentially equal pain control, with mean pain intensity scores of about 1.2 and 1.1 respectively on a four-point scale. About two thirds of patients needed 40 mg per day or less.²⁵ The main advantage of the controlled-release form is convenience and steadier blood levels, not superior pain relief. For nerve pain specifically, steady blood levels may matter because neuropathic pain tends to be continuous rather than episodic, and fluctuating drug levels can leave gaps during which pain breaks through.

One formulation that deserves mention is oxycodone combined with naloxone in a single tablet. Naloxone is an opioid antagonist that, when taken by mouth, acts mainly in the gut to reduce opioid-induced constipation without blocking pain relief in the brain. In the Cochrane review, one study tested adding an oxycodone-naloxone combination to stable pregabalin therapy and found no additional pain benefit over pregabalin plus placebo.¹ So while the combination tablet addresses a common side effect, it does not appear to improve the pain-relief picture for nerve pain.

When Oxycodone Might Reasonably Be Tried

Given all of the above, there are situations where oxycodone for nerve pain makes clinical sense and situations where it does not. The clearest case for trying it is when a person with painful diabetic neuropathy or postherpetic neuralgia has already tried first-line drugs like duloxetine, pregabalin, or gabapentin at adequate doses and still has unacceptable pain. In that scenario, adding oxycodone to an existing gabapentin regimen has the strongest evidence behind it. The evidence is weakest for using oxycodone as a first-choice drug for any form of nerve pain, and no major guideline recommends that approach.

It is also worth understanding what “moderate benefit” means in practice. The 44% response rate in the Cochrane review used a threshold of at least 30% pain reduction, not the elimination of pain. Most people who respond to oxycodone for nerve pain still have significant residual pain. The goal is usually to make pain manageable enough to sleep, work, and participate in physical therapy, not to make it disappear. Clinicians sometimes describe opioids for neuropathic pain as “taking the edge off” rather than providing complete relief, and the trial data largely support that framing. If you are considering oxycodone for nerve pain, knowing this can help calibrate expectations and make the decision about whether the side-effect trade-offs are worth it for you.